ALS (Amyotrophic Lateral Sclerosis) Mouse Models
Explore our advanced preclinical ALS mouse models, crucial for preclinical efficacy studies and understanding disease mechanisms
As a European preclinical neurology contract research organization (CRO), InnoSer provides you with a portfolio of Amyothropic Lateral Sclerosis (ALS) mouse models relevant for performing preclinical efficacy research studies. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs. InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
InnoSer offers multiple ALS mouse models relevant for preclinical research, including the SOD1-G93A transgenic ALS mouse model, TDP-43 transgenic mouse models and TDP-43 seeding models using recombinant or patient-derived seeds. However, as each model is unique, modelling distinct pathophysiological aspects of ALS, we recommend you discuss the most appropriate model with our neurology study directors.
ALS Mouse Models Options
SOD1-G93A Transgenic ALS Mouse Model
InnoSer offers unique behavioural research services with several different transgenic SOD1 mouse models.
TDP-43 Transgenic Mouse Model
InnoSer offers services with several different transgenic TDP-43 mouse models that replicate the TDP-43 proteinopathy in ALS and FTD patients.
TDP-43 Seeding Mouse Models
InnoSer offers extensive preclinical research experience with TDP-43 seeds using patient-derived brain extracts.
Learn more about the different ALS disease models by downloading a leaflet containing models, readouts, and example data.
ALS motor neuron disease
Pathology in the brain and spinal cord
Risk factors: C9orf72, SOD1, FUS, and TARDBP
Consequently, mice expressing the human protein with these mutations serve as highly promising models for evaluating therapeutics targeted at ALS.
The people behind the models
Jolien Beekens, PhD, Neurology Study Director
With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.
Thomas Vogels, PhD, Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Related Resources
View our in vivo neurology models overview with sample data
Accelerating ALS Drug Development: InnoSer’s Available In Vivo Models for Preclinical Research
Neurology research models and services overview page
info@innoserlaboratories.com